fig2

Figure 2. Schematic representation of the microbial group associations with CRC and BC. Differences in microbial composition and abundance are indicated according to the type of sample (stool, breast, or intestinal biopsies), the stage of cancer development, the molecular characteristics of the disease, and the approach/design of the study. The left side of the image shows breast microbiota profiles in different BC subtypes by 16S rRNA gene sequencing and pan-pathogen array (Pathochip array) and gut microbiota patterns associated with BC stage and prognosis by 16S rRNA gene and shotgun metagenomics. The right side shows differences in the intestinal mucosa microbiota detected by 16S rRNA gene sequencing, terminal restriction fragment length polymorphism, clone sequencing, and fluorescent in-situ hybridization analysis of the 16S rRNA genes for patients diagnosed with intestinal adenomatous polyps. Faecal samples were studied using 16S rRNA gene sequencing for patients diagnosed with HP and shotgun metagenomics and 16S rRNA for patients showing AP and high-risk adenomas (HRA: presence of high-degree dysplasia, tumours ≥ 10 mm, and/or presence of three or more adenomas of any size). Up or down arrows indicate higher or lower presence, respectively, of the microbial groups. The information represented has been obtained from studies showing significant changes in CRC^{[76,85,86,95-103]} and BC processes^{[115-117,123,124]}. AP: Adenomatous polyps; BC: breast cancer; CRC: colorectal cancer; ER: oestrogen receptor; FCR: fear of cancer recurrence; HER2: human epidermal growth factor receptor 2; HP: hyperplastic polyps; HRA: high-risk adenomas; PR: progesterone receptor; TNBC: triple-negative breast cancer. Figure created with BioRender.com.